ProShare Advisors’s Alaunos Therapeutics TCRT Stock Holding History

ProShare Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-105	Closed	-$2.07K	–	1973
2023 Q3	$2.07K	Buy	105 +1	+1%	+$43	﹤0.01%	1816
2023 Q2	$7.94K	Sell	104 -7	-6%	-$566	﹤0.01%	1846
2023 Q1	$10.5K	Sell	111 -22	-17%	-$2.1K	﹤0.01%	1764
2022 Q4	$12.9K	Buy	133 +12	+10%	+$1.74K	﹤0.01%	1824
2022 Q3	$31K	Buy	121 +9	+8%	+$2.61K	﹤0.01%	1699
2022 Q2	$21K	Sell	112 -299	-73%	-$28.6K	﹤0.01%	1763
2022 Q1	$41K	Sell	411 -97	-19%	-$12.4K	﹤0.01%	2127
2021 Q4	$83K	Buy	508 +22	+5%	+$4.83K	﹤0.01%	2225
2021 Q3	$133K	Sell	486 -135	-22%	-$41.3K	﹤0.01%	1865
2021 Q2	$246K	Buy	621 +44	+8%	+$20.5K	﹤0.01%	2018
2021 Q1	$312K	Buy	577 +42	+8%	+$26.1K	﹤0.01%	1783
2020 Q4	$202K	Buy	535 +361	+207%	+$144K	﹤0.01%	1843
2020 Q3	$66K	Sell	174 -19	-10%	-$8.39K	﹤0.01%	1569
2020 Q2	$95K	Buy	193 +121	+168%	+$54K	﹤0.01%	1571
2020 Q1	$26K	Sell	72 -73	-50%	-$37.8K	﹤0.01%	1132
2019 Q4	$103K	Buy	145 +23	+19%	+$15.8K	﹤0.01%	1690
2019 Q3	$78K	Buy	122 +29	+31%	+$23K	﹤0.01%	1571
2019 Q2	$81K	Sell	93 -2	-2%	-$1.38K	﹤0.01%	1551
2019 Q1	$55K	Buy	95 +3	+3%	+$1.25K	﹤0.01%	1610
2018 Q4	$26K	Sell	92 -15	-14%	-$5.93K	﹤0.01%	1548
2018 Q3	$52K	Sell	107 -9	-8%	-$3.86K	﹤0.01%	1720
2018 Q2	$52K	Buy	116 +4	+4%	+$2.54K	﹤0.01%	1749
2018 Q1	$66K	Sell	112 -18	-14%	-$11.2K	﹤0.01%	1663
2017 Q4	$81K	Buy	+130	New	+$93.4K	﹤0.01%	1741
2017 Q3	–	Sell	-77	Closed	-$72K	–	1405
2017 Q2	$72K	Sell	77 -16	-17%	-$15.7K	﹤0.01%	1410
2017 Q1	$89K	Sell	93 -37	-28%	-$34.5K	﹤0.01%	1518
2016 Q4	$104K	Buy	130 +50	+63%	+$45.1K	﹤0.01%	1681
2016 Q3	$68K	Sell	80 -19	-19%	-$15.3K	﹤0.01%	1431
2016 Q2	$82K	Buy	99 +5	+5%	+$5.44K	﹤0.01%	1534
2016 Q1	$104K	Sell	94 -17	-15%	-$17.4K	﹤0.01%	1518
2015 Q4	$139K	Buy	111 +38	+52%	+$62.9K	﹤0.01%	1604
2015 Q3	$98K	Sell	73 -24	-25%	-$39.6K	﹤0.01%	1388
2015 Q2	$174K	Sell	97 -20	-17%	-$31K	﹤0.01%	1539
2015 Q1	$189K	Buy	117 +1	+0.9%	+$1.48K	﹤0.01%	1729
2014 Q4	$88K	Sell	116 -99	-46%	-$52.6K	﹤0.01%	1862
2014 Q3	$85K	Sell	215 -49	-19%	-$23.6K	﹤0.01%	2197
2014 Q2	$159K	Sell	264 -279	-51%	-$155K	﹤0.01%	2254
2014 Q1	$373K	Buy	+543	New	+$364K	﹤0.01%	2097
2013 Q4	–	Sell	-283	Closed	-$168K	–	1826
2013 Q3	$168K	Sell	283 -6	-2%	-$2.7K	﹤0.01%	2263
2013 Q2	$91K	Buy	+289	New	+$80.3K	﹤0.01%	2279

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCA

Magnolia Capital Advisors Jackson, Mississippi $509M AUM 18.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

ProShare Advisors's TCRT Position: Q4 2023 in Review

ProShare Advisors sold out of Alaunos Therapeutics (TCRT) in Q4 2023, closing a stake of 105 shares — an estimated $2.07K sold.

ProShare Advisors first reported a position in TCRT in Q2 2013 and held it in 40 quarters. The position peaked at $373K in Q1 2014. 82 funds tracked by Wall St. Rank hold TCRT as of Q4 2023.

ProShare Advisors reported no remaining Alaunos Therapeutics position as of Q4 2023 after selling out during the quarter.
ProShare Advisors sold 105 Alaunos Therapeutics shares in Q4 2023, an estimated $2.07K.
ProShare Advisors first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 40 quarters.
ProShare Advisors's Alaunos Therapeutics position peaked at $373K in Q1 2014.
82 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2023.

Based on ProShare Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.